Smad4 Polyclonal Antibody

Formalin-fixed and paraffin embedded human colon carcinoma labeled with Anti-Smad4 Polyclonal Antibody, Unconjugated (bs-0585R) at 1:200, followed by conjugation to the secondary antibody and DAB staining

$Cancer circulating cells\u00a0were obtained from patient whole blood, after AutoMAC depletion, CD45 negative cell were stained with EpCAM, MET, p16, Smad4 (Rabbit Anti-Smad4 Polyclonal Antibody, bs-0585R) and FxCycle etc, the imagery ware generated by Image Stream X \u00a0(Amnis). This image was generously provided by Peng Xu at the University of Chicago as part of the Bioss Discovery Program.\\n$

Cancer circulating cells\u00a0were obtained from patient whole blood, after AutoMAC depletion, CD45 negative cell were stained with EpCAM, MET, p16, Smad4 (Rabbit Anti-Smad4 Polyclonal Antibody, bs-0585R) and FxCycle etc, the imagery ware generated by Image Stream X \u00a0(Amnis). This image was generously provided by Peng Xu at the University of Chicago as part of the Bioss Discovery Program.\\n

Applications

WB
IHC-P
IF(IHC-P)

Reactivity

Human

Predicted Reactivity

Mouse
Rat
Dog
Cow
Sheep
Pig
Horse
Chicken
Rabbit
Zebrafish

Overview
Catalog #	bs-0585R
Product Name	Smad4 Polyclonal Antibody
Applications	WB IHC-P IF(IHC-P)
Reactivity	Human
Predicted Reactivity	Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Chicken, Rabbit, Zebrafish
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human Smad4
Clonality	Polyclonal
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20C for 12 months.
Target
Gene ID	4089
Swiss Prot	Q13485
Synonyms	JIP; DPC4; MADH4; MYHRS; Mothers against decapentaplegic homolog 4; MAD homolog 4; Mothers against DPP homolog 4; Deletion target in pancreatic carcinoma 4; SMAD family member 4; SMAD 4; Smad4; hSMAD4
Background	In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions (By similarity). Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling. Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for syngernistic transcriptional activity in response to TGF-beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IF(IHC-P)	1:50-200